Drug details
Mayzent (siponimod tablets)
type of Sphingosine 1-Phosphate Receptor Modulators
Mayzent (siponimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
This drug may have the following side effects:
- shortness of breath,
- nausea,
- headache,
- blurred vision,
- vomiting,
- loss of appetite,
- fever,
- chills,
- tiredness,
- hives,
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- confusion,
- vision problems,
- dark urine,
- body aches,
- yellowing of the skin or eyes (jaundice),
- eye pain,
- increased sensitivity to light
- cold sores,
- seizure,
- upper stomach pain,
- slow or irregular heartbeats,
- change in mental status,
- sores in your mouth and throat,
- sores on your genital area or anal area,
- skin changes,
- unusual moles that change in color or size,
- neck stiffness, and
The following drugs are related to Mayzent, either as a replacement or used together:
- Lemtrada (alemtuzumab injection for intravenous infusion)
- Aubagio (teriflunomide tablets)
- Avonex (interferon beta-1a)
- Lyvispah (baclofen oral granules)
- Ozobax (baclofen oral solution)
- Fleqsuvy (baclofen oral suspension)
- Bafiertam (monomethyl fumarate delayed-release capsules)
- Betaseron (interferon beta-1b)
- Briumvi (ublituximab-xiiy injection)
- Mavenclad (cladribine tablets)
- Copaxone (glatiramer acetate)
- Extavia (interferon beta-1b kit)
- Gilenya (fingolimod capsules)
- Tascenso ODT (fingolimod orally disintegrating tablets)
- Glatopa (glatiramer acetate injection)
- Rebif (interferon beta-1a)
- Kesimpta (ofatumumab injection)
- Novantrone (mitoxantrone for injection concentrate)
- Tysabri (natalizumab)
- Ocrevus (ocrelizumab injection)
- Plegridy (peginterferon beta-1a injection for subcutaneous use)
- Ponvory (ponesimod tablets)